Key Highlights

  • Invion (ASX:IVX) shares were up 12.12% at $0.037 during the trading session on 23 October 2026, while the S&P/ASX 200 was down 0.35%.
  • In an announcement dated 21 October 2026, Invion reported funding agreements expected to cover up to approximately 85% of its clinical trial costs.
  • Point8 Capital has committed up to A$25 million in co-funding, and Rockford Capital a facility of up to A$7.5 million across FY27 and FY28.

Invion Limited (ASX:IVX) shares were up 12.12% at $0.037 during the trading session on 23 October 2026, at 12:04 pm, while the S&P/ASX 200 stood at 8,762.60, down 0.35% (30.60 points). Invion is a Melbourne-based life-science company developing the Photosoft technology for cancers, ophthalmic and infectious diseases. Its latest update, dated 21 October 2026, outlined two financing arrangements expected to cover up to approximately 85% of its clinical trial costs. That announcement predates this session, so it is not presented as an explanation for the day's price movement.

Two Funding Arrangements for Clinical Programs

In its announcement dated 21 October 2026, Invion said it had secured two complementary financing arrangements expected to cover up to approximately 85% of its current and future clinical development programs, including the ongoing non-melanoma skin cancer (NMSC) trial and upcoming anogenital cancer trials. Funds are released when invoices from clinical research organisations (CROs) fall due.

Point8 Capital Pty Ltd (Point8) will fund 50% of CRO invoices, while Rockford RDF Pty Ltd as trustee for the Rockford RDF Unit Trust (Rockford Capital) will fund up to about 35% of the total invoice amount.

Point8 Co-Funding Deed and Option Terms

Under a binding Co-Funding and Option Deed, Point8 committed to a multi-year co-funding facility of up to A$25 million, contributing half of each clinical milestone payment. Invion said it intends to draw on the facility in stages.

In consideration, Invion will grant Point8 or its nominee 11,055,313 unlisted options, equal to 10% of its issued share capital on a non-diluted basis, subject to shareholder approval under ASX Listing Rule 7.1. The exercise price is $0.03639, the five-day volume weighted average price before the deed took effect, with a five-year term. Exercise is conditional on a program candidate reaching Phase 3 and on funding being provided.

Rockford Capital R&D Tax Incentive Facility

Rockford Capital committed to a secured loan facility of up to A$7.5 million in aggregate across FY27 and FY28, based on 34.8% of eligible R&D tax incentive (RDTI) expenditure, letting Invion fund CRO invoices ahead of receiving refundable RDTI offsets. Invion granted a first ranking security interest over its refundable RDTI offset receivables.

Terms include a 16.0% annual interest rate, a drawdown fee of 1.50% of each amount advanced and a final maturity date of 30 April 2029. Invion also agreed to issue A$50,000 of shares (1,374,003 shares at $0.03639) as an arrangement fee, subject to shareholder approval.

About the Company and Business Overview

Invion Limited is listed on the ASX under IVX and is based at 385 Bourke Street, Melbourne. It describes itself as a life-science company leading research and development of the Photosoft technology for cancers, ophthalmic and infectious diseases, and holds the global exclusive licence for multiple cancer and non-cancer indications.

Photosoft is being developed as a Next Generation Photodynamic Therapy, which uses non-toxic photosensitisers and light to selectively kill cancer cells. The company plans to advance its NMSC trial to Phase II, as announced on 19 October 2026, and has partnered with the Peter MacCallum Cancer Centre to start an anogenital trial in the coming year. The US FDA has granted Orphan Drug Designation to lead candidate INV043 for anal cancer.

Related Sector Context

Invion operates in clinical-stage biotechnology, where companies typically carry no approved products and rely on external funding, grants and tax incentives to finance trials.

The S&P/ASX 200 stood at 8,762.60 at 12:04 pm on 23 October 2026, down 0.35%, while Invion shares were higher at $0.037 in the same session. The benchmark covers large companies and says little about an individual development-stage company.

Risks to Weigh In

Invion noted that both agreements are subject to usual funding risks and depend on Point8 and Rockford Capital meeting their obligations, with no assurance funding will be received or that it will not be withdrawn.

The option grant and arrangement fee shares require shareholder approval. Rockford Capital drawdowns are conditional on either receipt of the Point8 contribution or Invion holding sufficient cash to pay the CRO invoice, and the facility carries a 16.0% interest rate. Clinical outcomes remain uncertain. Shareholders will also be asked to consider the proposals.

Catalysts on Watch

The announcement dated 21 October 2026 points to shareholder approval under ASX Listing Rule 7.1, staged drawdowns under the Point8 facility, the advance of the NMSC trial to Phase II and the start of an anogenital trial in the coming year. Rockford Capital's drawdowns are aligned to CRO invoice payment dates, so the timing of funding depends on when those invoices fall due.

Where Things Stand

Invion shares traded at $0.037, up 12.12%, at 12:04 pm on 23 October 2026, with the S&P/ASX 200 down 0.35%. The company's update dated 21 October 2026 set out facilities of up to A$25 million from Point8 and A$7.5 million from Rockford Capital. Together, the facilities are expected to cover up to approximately 85% of clinical trial costs.